192 related articles for article (PubMed ID: 18000940)
1. Heteroaryl-substituted 4-(1H-pyrazol-1-yl)-5,6-dihydro-1H-pyrrolo[2,3-d]pyrimidine derivatives as potent and selective corticotropin-releasing factor receptor-1 antagonists.
Sabbatini FM; Di Fabio R; St-Denis Y; Capelli AM; Castiglioni E; Contini S; Donati D; Fazzolari E; Gentile G; Micheli F; Pavone F; Rinaldi M; Pasquarello A; Zampori MG; Di Felice P; Zarantonello P; Arban R; Perini B; Vitulli G; Benedetti R; Oliosi B; Worby A
ChemMedChem; 2008 Feb; 3(2):226-9. PubMed ID: 18000940
[No Abstract] [Full Text] [Related]
2. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
[TBL] [Abstract][Full Text] [Related]
3. Substituted tetraazaacenaphthylenes as potent CRF1 receptor antagonists for the treatment of depression and anxiety.
St-Denis Y; Di Fabio R; Bernasconi G; Castiglioni E; Contini S; Donati D; Fazzolari E; Gentile G; Ghirlanda D; Marchionni C; Messina F; Micheli F; Pavone F; Pasquarello A; Sabbatini FM; Zampori MG; Arban R; Vitulli G
Bioorg Med Chem Lett; 2005 Aug; 15(16):3713-6. PubMed ID: 15946843
[TBL] [Abstract][Full Text] [Related]
4. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE
Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140
[TBL] [Abstract][Full Text] [Related]
5. 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.
Saito T; Obitsu T; Kondo T; Matsui T; Nagao Y; Kusumi K; Matsumura N; Ueno S; Kishi A; Katsumata S; Kagamiishi Y; Nakai H; Toda M
Bioorg Med Chem; 2011 Sep; 19(18):5432-45. PubMed ID: 21865047
[TBL] [Abstract][Full Text] [Related]
6. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.
Chen YL; Mansbach RS; Winter SM; Brooks E; Collins J; Corman ML; Dunaiskis AR; Faraci WS; Gallaschun RJ; Schmidt A; Schulz DW
J Med Chem; 1997 May; 40(11):1749-54. PubMed ID: 9171885
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.
Hartz RA; Nanda KK; Ingalls CL; Ahuja VT; Molski TF; Zhang G; Wong H; Peng Y; Kelley M; Lodge NJ; Zaczek R; Gilligan PJ; Trainor GL
J Med Chem; 2004 Sep; 47(19):4741-54. PubMed ID: 15341489
[TBL] [Abstract][Full Text] [Related]
10. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines.
Gillespie RJ; Cliffe IA; Dawson CE; Dourish CT; Gaur S; Jordan AM; Knight AR; Lerpiniere J; Misra A; Pratt RM; Roffey J; Stratton GC; Upton R; Weiss SM; Williamson DS
Bioorg Med Chem Lett; 2008 May; 18(9):2924-9. PubMed ID: 18411049
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
[TBL] [Abstract][Full Text] [Related]
12. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy.
Li YW; Hill G; Wong H; Kelly N; Ward K; Pierdomenico M; Ren S; Gilligan P; Grossman S; Trainor G; Taub R; McElroy J; Zazcek R
J Pharmacol Exp Ther; 2003 Apr; 305(1):86-96. PubMed ID: 12649356
[TBL] [Abstract][Full Text] [Related]
13. Potential uses of corticotropin-releasing hormone antagonists.
Zoumakis E; Rice KC; Gold PW; Chrousos GP
Ann N Y Acad Sci; 2006 Nov; 1083():239-51. PubMed ID: 17148743
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP
J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945
[TBL] [Abstract][Full Text] [Related]
15. 2-Arylpyrimidines: novel CRF-1 receptor antagonists.
Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Krause JE; Hutchison A; Horvath RF; Ge P; Kehne J; Hoffman D; Chandrasekhar J; Doller D; Hodgetts KJ
Bioorg Med Chem Lett; 2008 Aug; 18(16):4486-90. PubMed ID: 18672365
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
Takahashi Y; Hashizume M; Shin K; Terauchi T; Takeda K; Hibi S; Murata-Tai K; Fujisawa M; Shikata K; Taguchi R; Ino M; Shibata H; Yonaga M
J Med Chem; 2012 Oct; 55(19):8450-63. PubMed ID: 22971011
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.
Han X; Michne JA; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Dubowchik GM
Bioorg Med Chem Lett; 2005 Sep; 15(17):3870-3. PubMed ID: 15990298
[TBL] [Abstract][Full Text] [Related]
18. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
Dyck B; Grigoriadis DE; Gross RS; Guo Z; Haddach M; Marinkovic D; McCarthy JR; Moorjani M; Regan CF; Saunders J; Schwaebe MK; Szabo T; Williams JP; Zhang X; Bozigian H; Chen TK
J Med Chem; 2005 Jun; 48(12):4100-10. PubMed ID: 15943483
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Nielsen DM; Carey GJ; Gold LH
Eur J Pharmacol; 2004 Sep; 499(1-2):135-46. PubMed ID: 15363960
[TBL] [Abstract][Full Text] [Related]
20. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.
Wustrow DJ; Capiris T; Rubin R; Knobelsdorf JA; Akunne H; Davis MD; MacKenzie R; Pugsley TA; Zoski KT; Heffner TG; Wise LD
Bioorg Med Chem Lett; 1998 Aug; 8(16):2067-70. PubMed ID: 9873487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
